Curis (CRIS), Debiopharm Initiate Debio 0932 Phase I StreetInsider.com (subscription) This dose escalation study is designed to determine the safety and maximum tolerated dose of Debio 0932 in combination with everolimus, in previously treated patients with advanced/metastatic RCC. The pharmacokinetic profiles and any potential drug ... |
